A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation
NCT05528406 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2022-09-06
Summary
An Open-label, Multicenter Phase II Clinical Study to Evaluate Safety, Efficacy and PK of HLX208 (BRAF V600E Inhibitor) in Advanced Solid Tumor With BRAF V600 Mutation
Conditions
Interventions
- DRUG
-
HLX208
900mg bid po
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-10-20
- Primary Completion
- 2024-10-30
- Completion
- 2025-06-01
More Related Trials
-
A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors
NCT01143753 ·Status: COMPLETED ·Phase: PHASE1
-
HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies
NCT06649708 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation
NCT06536400 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors
NCT05442996 ·Status: UNKNOWN ·Phase: PHASE1
-
Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2
NCT03916094 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors
NCT07274813 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
NCT02648490 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors
NCT03757936 ·Status: UNKNOWN ·Phase: PHASE1
-
A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma
NCT07333469 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
NCT04443088 ·Status: RECRUITING ·Phase: PHASE1
-
First-in-Human Study of MS201408-0005A as Single Agent and in Combinations
NCT03306420 ·Status: TERMINATED ·Phase: PHASE1
-
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors
NCT00743067 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors
NCT06001580 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
NCT01543698 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
NCT06707610 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours
NCT06247657 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor
NCT04797468 ·Status: WITHDRAWN ·Phase: PHASE1
-
Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
NCT02601274 ·Status: TERMINATED ·Phase: PHASE1
-
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors
NCT05650242 ·Status: RECRUITING ·Phase: PHASE1
-
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
NCT06190886 ·Status: RECRUITING ·Phase: PHASE1
-
Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
NCT06936735 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
NCT05830539 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
NCT05801237 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase I Study of PLX038 in Patients With Advanced Solid Tumors
NCT02646852 ·Status: COMPLETED ·Phase: PHASE1
-
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
NCT06380660 ·Status: RECRUITING ·Phase: PHASE1/PHASE2